Sun Pharmaceutical Industries Limited has informed the Exchange regarding Change in Auditors of the company.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty 100 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma's board met on May 22, 2025 and approved audited financial results with an unmodified (clean) audit opinion. On a standalone basis, Q4 FY25 revenue from operations rose to Rs. 71,857 million (vs Rs. 56,391 million in Q4 FY24), with profit after tax jumping to Rs. 20,005 million (vs Rs. 8,676 million). Full-year FY25 standalone revenue grew to Rs. 230,033 million and PAT to Rs. 42,826 million, taking EPS to Rs. 17.8. Consolidated FY25 revenue from operations was Rs. 525,784 million. The board recommended a final dividend of Rs. 5.50 per share (face value Rs. 1) on top of the Rs. 10.50 interim dividend already paid, with record date July 7, 2025. Ms. Vidhi Shanghvi was appointed as Whole-time Director for five years, and long-serving non-executive director Mr. Sudhir Valia will retire and not seek re-appointment. M/s. KJB & CO LLP was appointed as Secretarial Auditor for five years, and the 33rd AGM is set for July 31, 2025.
Strong earnings beat with ~50% YoY standalone PAT growth and continued dividend payouts are positive for shareholders. The appointment of Ms. Vidhi Shanghvi as Whole-time Director signals promoter-family succession planning, while the orderly exit of Mr. Sudhir Valia (also a Shanghvi family member) is part of routine board refreshment. Statutory auditor S R B C & Co LLP continues, so the headline on auditor change relates only to the new secretarial auditor and should not cause concern.